Harmful molecular mechanisms in sepsis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644–1655 (1992).
Remick, D. G. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr. Pharm. Des. 9, 75–82 (2003).
Hotchkiss, R. S. & Nicholson, D. W. Apoptosis and caspases regulate death and inflammation in sepsis. Nature Rev. Immunol. 6, 813–822 (2006).
Solomkin, J. S., Jenkins, M. K., Nelson, R. D., Chenoweth, D. & Simmons, R. L. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery 90, 319–327 (1981).
Harrington, L. E. et al. Interleukin-17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123–1132 (2005).
Hotchkiss, R. S. et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J. Immunol. 174, 5110–5118 (2005).
Hotchkiss, R. S. et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J. Immunol. 168, 2493–2500 (2002).
Kim, K. D. et al. Adaptive immune cells temper initial innate responses. Nature Med. 13, 1248–1252 (2007).
Huber-Lang, M. et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nature Med. 12, 682–687 (2006). This study shows that thrombin can act as a C5 convertase, which indicates that there is direct crosstalk between the coagulation and complement systems.
Flierl, M. A. et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 449, 721–725 (2007). This publication identifies phagocytes as a source of catecholamines, which enhance the inflammatory response.
Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukocyte Biol. 81, 1–5 (2007).
Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085–2088 (1998). In this study, TLR4 is defined as the recognition receptor for LPS.
Ohto, U., Fukase, K., Miyake, K. & Satow, Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316, 1632–1634 (2007).
Kim, H. M. et al. Crystal structure of the TLR4–MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130, 906–917 (2007).
Park, J. S. et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370–7377 (2004).
Hawlisch, H. et al. C5a negatively regulates Toll-like receptor-4-induced immune responses. Immunity 22, 415–426 (2005). This study describes a negative effect of C5a on TLR4-mediated responses as an important mechanism for regulating T H 1-cell polarization in response to activation of the innate and adaptive immune systems.
Zhang, X. et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110, 228–236 (2007).
Koleva, M. et al. Induction of anaphylatoxin C5a receptors in rat hepatocytes by lipopolysaccharide in vivo: mediation by interleukin-6 from Kupffer cells. Gastroenterology 122, 697–708 (2002).
Clark, S. R. et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Med. 13, 463–469 (2007).
Daubeuf, B. et al. TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J. Immunol. 179, 6107–6114 (2007).
McMasters, K. M., Peyton, J. C., Hadjiminas, D. J. & Cheadle, W. G. Endotoxin and tumour necrosis factor do not cause mortality from caecal ligation and puncture. Cytokine 6, 530–536 (1994).
van der Poll, T. & Opal, S. M. Host–pathogen interactions in sepsis. Lancet Infect. Dis. 8, 32–43 (2008).
Ritis, K. et al. A novel C5a receptor–tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 177, 4794–4802 (2006).
Riedemann, N. C. et al. Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils. J. Immunol. 173, 1355–1359 (2004).
Rittirsch, D. et al. Functional roles for C5a receptors in sepsis. Nature Med. 14, 551–557 (2008). This study indicates that both C5a receptors, C5AR and C5L2, synergistically contribute to harmful events in sepsis. In contrast to previous discussions, the authors conclude that C5L2 seems to be a functional receptor rather than a decoy receptor.
Calandra, T. & Roger, T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nature Rev. Immunol. 3, 791–800 (2003).
Lubetsky, J. B. et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976–24982 (2002).
Shi, X. et al. CD44 is the signaling component of the macrophage migration inhibitory factor–CD74 receptor complex. Immunity 25, 595–606 (2006).
Bernhagen, J. et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756–759 (1993).
Leng, L. et al. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467–1476 (2003).
Mitchell, R. A., Metz, C. N., Peng, T. & Bucala, R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274, 18100–18106 (1999).
Calandra, T. et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Med. 6, 164–170 (2000). This study defines a crucial role for MIF in the pathogenesis of septic shock and identifies MIF as a new target for therapeutic intervention.
Al-Abed, Y. et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280, 36541–36544 (2005).
Muller, S. et al. New EMBO members' review. The double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20, 4337–4340 (2001).
Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248–251 (1999). This work defined, for the first time, an extracellular role for HMGB1 as a pro-inflammatory mediator in endotoxaemia and sepsis.
Lotze, M. T. & Tracey, K. J. High mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Rev. Immunol. 5, 331–342 (2005).
Kim, J. Y. et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am. J. Physiol. Lung Cell. Mol. Physiol. 288, L958–L965 (2005).
Wang, H. et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Med. 10, 1216–1221 (2004).
Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191–195 (2002).
Qin, S. et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203, 1637–1642 (2006).
Hori, O. et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270, 25752–25761 (1995).
Sha, Y., Zmijewski, J., Xu, Z. & Abraham, E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180, 2531–2537 (2008).
Klune, J. R., Dhupar, R., Cardinal, J., Billiar, T. R. & Tsung, A. HMGB1: endogenous danger signaling. Mol. Med. 14, 476–484 (2008).
Sunden-Cullberg, J. et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit. Care Med. 33, 564–573 (2005).
Liliensiek, B. et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113, 1641–1650 (2004).
Yang, H. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl Acad. Sci. USA 101, 296–301 (2004).
Weaver, C. T., Hatton, R. D., Mangan, P. R. & Harrington, L. E. IL-17 family cytokines and the expanding diversity of effector T-cell lineages. Annu. Rev. Immunol. 25, 821–852 (2007).
Flierl, M. A. et al. Adverse functions of IL-17A in experimental sepsis. FASEB J. 22, 2198–2205 (2008).
Nakae, H. et al. Serum complement levels and severity of sepsis. Res. Commun. Chem. Pathol. Pharmacol. 84, 189–195 (1994).
Gerard, C. Complement C5a in the sepsis syndrome — too much of a good thing? N. Engl. J. Med. 348, 167–169 (2003).
Kildsgaard, J. et al. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J. Immunol. 165, 5406–5409 (2000).
Francis, K. et al. Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB J. 17, 2266–2268 (2003).
Huber-Lang, M. S. et al. Complement-induced impairment of innate immunity during sepsis. J. Immunol. 169, 3223–3231 (2002).
Huber-Lang, M. et al. Role of C5a in multiorgan failure during sepsis. J. Immunol. 166, 1193–1199 (2001).
Riedemann, N. C. et al. C5a receptor and thymocyte apoptosis in sepsis. FASEB J. 16, 887–888 (2002).
Flierl, M. A. et al. The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. PLoS ONE 3, e2560 (2008).
Laudes, I. J. et al. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am. J. Pathol. 160, 1867–1875 (2002).
Niederbichler, A. D. et al. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J. Exp. Med. 203, 53–61 (2006).
Gerard, N. P. et al. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J. Biol. Chem. 280, 39677–39680 (2005).
Chen, N. J. et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446, 203–207 (2007).
Huber-Lang, M. et al. Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J. Immunol. 174, 1104–1110 (2005).
Zeerleder, S. et al. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin. Diagn. Lab. Immunol. 10, 529–535 (2003).
Caliezi, C. et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit. Care Med. 30, 1722–1728 (2002).
Flierl, M. A. et al. Functions of the complement components C3 and C5 during sepsis. FASEB J. 27 June 2008 (doi:10.1096/fj.08-110595).
Levi, M. & Ten Cate, H. Disseminated intravascular coagulation. N. Engl. J. Med. 341, 586–592 (1999).
Abraham, E. Coagulation abnormalities in acute lung injury and sepsis. Am. J. Respir. Cell. Mol. Biol. 22, 401–404 (2000).
Esmon, C. T. The impact of the inflammatory response on coagulation. Thromb. Res. 114, 321–327 (2004).
Stouthard, J. M. et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb. Haemost. 76, 738–742 (1996).
Bevilacqua, M. P. et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc. Natl Acad. Sci. USA 83, 4533–4537 (1986).
Bernard, G. R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699–709 (2001). This study showed that treatment with activated protein C significantly decreased mortality in patients with severe sepsis, but might be associated with an increased risk of bleeding.
Maugeri, N. et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J. Thromb. Haemost. 4, 1323–1330 (2006).
Osterud, B. & Flaegstad, T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb. Haemost. 49, 5–7 (1983).
Zeerleder, S., Schroeder, V., Hack, C. E., Kohler, H. P. & Wuillemin, W. A. TAFI and PAI-1 levels in human sepsis. Thromb. Res. 118, 205–212 (2006).
Levi, M., de Jonge, E. & van der Poll, T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann. Med. 36, 41–49 (2004).
Joyce, D. E., Gelbert, L., Ciaccia, A., DeHoff, B. & Grinnell, B. W. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276, 11199–11203 (2001).
Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M. & Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880–1882 (2002).
Niessen, F. et al. Dendritic cell PAR1–S1P3 signalling couples coagulation and inflammation. Nature 452, 654–658 (2008).
Kaneider, N. C. et al. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nature Immunol. 8, 1303–1312 (2007).
Fukudome, K. & Esmon, C. T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J. Biol. Chem. 269, 26486–26491 (1994).
Ito, T. et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J. Thromb. Haemost. 5, 109–116 (2007).
Cheng, T. et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nature Med. 9, 338–342 (2003).
Kerschen, E. J. et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J. Exp. Med. 204, 2439–2448 (2007).
Krem, M. M. & Di Cera, E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem. Sci. 27, 67–74 (2002).
Ghebrehiwet, B., Silverberg, M. & Kaplan, A. P. Activation of the classical pathway of complement by Hageman factor fragment. J. Exp. Med. 153, 665–676 (1981).
Goldberger, G. et al. NH2-terminal structure and cleavage of guinea pig pro-C3, the precursor of the third complement component. J. Biol. Chem. 256, 12617–12619 (1981).
Thoman, M. L., Meuth, J. L., Morgan, E. L., Weigle, W. O. & Hugli, T. E. C3d-K, a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation. J. Immunol. 133, 2629–2633 (1984).
Campbell, W., Okada, N. & Okada, H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol. Rev. 180, 162–167 (2001).
Wojta, J. et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 100, 517–523 (2002).
Muhlfelder, T. W. et al. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J. Clin. Invest. 63, 147–150 (1979).
Krarup, A., Wallis, R., Presanis, J. S., Gal, P. & Sim, R. B. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2, e623 (2007).
Rezende, S. M., Simmonds, R. E. & Lane, D. A. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S–C4b binding protein complex. Blood 103, 1192–1201 (2004).
Sternberg, E. M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nature Rev. Immunol. 6, 318–328 (2006).
Elenkov, I. J., Wilder, R. L., Chrousos, G. P. & Vizi, E. S. The sympathetic nerve — an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52, 595–638 (2000).
Bergquist, J., Tarkowski, A., Ekman, R. & Ewing, A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc. Natl Acad. Sci. USA 91, 12912–12916 (1994).
Munford, R. S. & Tracey, K. J. Is severe sepsis a neuroendocrine disease? Mol. Med. 8, 437–442 (2002).
Wang, H. et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 421, 384–388 (2003). This work shows that the α 7 -nicotinic acetylcholine receptor is required for acetylcholine-mediated inhibition of cytokine production by macrophages, which is also known as the cholinergic anti-inflammatory pathway.
Tracey, K. J. Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 117, 289–296 (2007).
Huston, J. M. et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J. Exp. Med. 203, 1623–1628 (2006).
Huston, J. M. et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit. Care Med. 35, 2762–2768 (2007).
Annane, D. et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am. J. Respir. Crit. Care Med. 160, 458–465 (1999).
Bergmann, M. & Sautner, T. Immunomodulatory effects of vasoactive catecholamines. Wien. Klin. Wochenschr. 114, 752–761 (2002).
Oberbeck, R. Catecholamines: physiological immunomodulators during health and illness. Curr. Med. Chem. 13, 1979–1989 (2006).
Oberbeck, R. et al. Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation 11, 214–223 (2004).
Kradin, R., Rodberg, G., Zhao, L. H. & Leary, C. Epinephrine yields translocation of lymphocytes to the lung. Exp. Mol. Pathol. 70, 1–6 (2001).
Ackerman, K. D., Madden, K. S., Livnat, S., Felten, S. Y. & Felten, D. L. Neonatal sympathetic denervation alters the development of in vitro spleen cell proliferation and differentiation. Brain Behav. Immun. 5, 235–261 (1991).
Spengler, R. N., Allen, R. M., Remick, D. G., Strieter, R. M. & Kunkel, S. L. Stimulation of α-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J. Immunol. 145, 1430–1434 (1990).
Freestone, P. P. et al. Growth stimulation of intestinal commensal Escherichia coli by catecholamines: a possible contributory factor in trauma-induced sepsis. Shock 18, 465–470 (2002).
Zhou, M., Das, P., Simms, H. H. & Wang, P. Gut-derived norepinephrine plays an important role in up-regulating IL-1β and IL-10. Biochim. Biophys. Acta 1740, 446–452 (2005).
Yang, S., Zhou, M., Chaudry, I. H. & Wang, P. Norepinephrine-induced hepatocellular dysfunction in early sepsis is mediated by activation of α2-adrenoceptors. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G1014–G1021 (2001).
Yang, S., Koo, D. J., Zhou, M., Chaudry, I. H. & Wang, P. Gut-derived norepinephrine plays a critical role in producing hepatocellular dysfunction during early sepsis. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G1274–G1281 (2000).
Zhou, M. et al. The role of Kupffer cell α2-adrenoceptors in norepinephrine-induced TNF-α production. Biochim. Biophys. Acta 1537, 49–57 (2001).
Dombrovskiy, V. Y., Martin, A. A., Sunderram, J. & Paz, H. L. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit. Care Med. 35, 1244–1250 (2007). This publication is the most recent study to describe the epidemiology of sepsis in the United States. Most importantly, the rates of hospitalization and mortality from severe sepsis increased significantly over the observation period from 1993 to 2003.
Rittirsch, D., Hoesel, L. M. & Ward, P. A. The disconnect between animal models of sepsis and human sepsis. J. Leukocyte Biol. 81, 137–143 (2007).
Levy, M. M. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250–1256 (2003).
Calvano, S. E. et al. A network-based analysis of systemic inflammation in humans. Nature 437, 1032–1037 (2005).
Westfall, T. C. & Westfall, D. P. in Goodman & Gilman's The Pharmacological Basis of Therapeutics (eds Brunton, L. L., Lazo, J. S. & Parker, K. L.) 153–158 (McGraw-Hill, New York, 2006).